PharmiWeb.com - Global Pharma News & Resources
04-May-2021

(COVID-19 Updates) Chordoma Disease Therapeutics Market – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027 | Coherent Market Insights

SEATTLE, May 04, 2021, (PHARMIWEB) —

Overview:

Chordoma is rare cancer that affects the spine or the area between the base of the skull and the tailbone. A chordoma is a form of sarcoma, which are cancerous tumors of the bones and soft tissues. The most common sacral and cervical spine tumors are Chordomas.

Chordoma tumors may impact the spine, brain, and nerves, causing tingling, numbness, fatigue, loss of bladder or bowel control, sexual dysfunction, vision problems, endocrine problems, and swallowing problems.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3979

Chordoma are handled differently depending on their size, position, and appearance. Chordoma can recur or spread in other parts of the body even after surgical treatment. Chordoma usually affect the bones, lungs, liver, and lymph nodes. Surgery, radiation therapy, targeted therapy, and advanced chemotherapies are among the treatment choices. Targeted therapy, in which medications are used to directly target cancerous cells, is the most effective procedure.

Drivers:

The rise in drug approvals from regulatory authorities for chordoma treatment is expected to fuel the growth of the chordoma disease therapeutics market. For instance, The United States Food and Drug Administration (FDA) granted orphan drug status to Bavarian Nordic A/BN-Brachyury, S’s a novel cancer vaccine indicated for the treatment of chordoma, in May 2018.

Key players focusing on the adoption of strategies such as collaborations and agreements to strengthen their position in the market are expected to drive the growth of the chordoma disease therapeutic market. For instance, Biothera Pharmaceuticals signed a licensing agreement with Cipla Limited in January 2019 for BAT1706, a possible bevacizumab biosimilar. Cipla Limited secured the rights to distribute and sell the biosimilar in emerging markets as part of this deal.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3979

Covid-19 Impact:

Chemotherapy and other cancer therapies may weaken cancer patients’ immune systems, raising their risk of infection. As a result, people with cancers like chordoma are more likely to experience severe COVID-19-related complications. However, due to the vital nature of chordoma disease, regulatory authorities have advised against delaying or postponing chemotherapy or immunotherapy for chordoma disease care.

Healthcare facilities are introducing telehealth solutions to deliver services to cancer patients while preserving social distance in order to tackle the COVID-19 pandemic without jeopardising cancer patients’ health. Patients can make virtual consultation appointments with their physicians. To combat the spread of COVID-19 infection, healthcare providers are taking the following steps.

  • Visitors are not permitted into hospitals, where only emergency cases are dealt with.
  • All patients entering hospitals are being checked for potential COVID-19 symptoms.
  • Healthcare providers are allowing patients to use telemedicine systems to schedule appointments.

Restraints:

Chemotherapeutic drugs approved for the treatment of chordoma are not always successful and can cause nausea, headaches, and hair loss, which is expected to limit market growth over the forecast period. The low prevalence of the disease and treatment limitations, as well as the high cost of diagnosis, treatment, and research and development, are all factors limiting the market growth.

The global chordoma disease therapeutics market size is expected to be valued at US$ 5,296.31 million in 2020 and is expected to exhibit a CAGR of 6.7% over the forecast period (2020-2027).

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3979

Market Taxonomy:

Chordoma Disease Therapeutics Market, by Drug Class, is segmented into:

  • Antimetabolites
  • Anthracycline
  • VEGFR Inhibitors
  • EGFR Inhibitor
  • Others

By Treatment Type:

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Others

By End User:

  • Hospitals
  • Clinics
  • Oncology Centers
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

 Key Players:

Major players operating in the global chordoma disease therapeutics market include Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Bristol-Myers Squibb, and Company, Novartis International AG, Bayer AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/chordoma-disease-therapeutics-market-3247

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 04-May-2021